527 related articles for article (PubMed ID: 36458008)
1. CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Ghazi B; El Ghanmi A; Kandoussi S; Ghouzlani A; Badou A
Front Immunol; 2022; 13():978195. PubMed ID: 36458008
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in CAR-T cells therapy for colorectal cancer.
Qin X; Wu F; Chen C; Li Q
Front Immunol; 2022; 13():904137. PubMed ID: 36238297
[TBL] [Abstract][Full Text] [Related]
5. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract][Full Text] [Related]
6. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
Wang H; Pan W
Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614
[TBL] [Abstract][Full Text] [Related]
7. Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.
Qian S; Villarejo-Campos P; Guijo I; Hernández-Villafranca S; García-Olmo D; González-Soares S; Guadalajara H; Jiménez-Galanes S; Qian C
Front Immunol; 2022; 13():841425. PubMed ID: 35401510
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer.
Sur D; Havasi A; Cainap C; Samasca G; Burz C; Balacescu O; Lupan I; Deleanu D; AlexandruIrimie
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31936611
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cysts as a validating tool for CAR therapy.
Dillard P; Lie M; Baken E; Lobert VH; Benard E; Köksal H; Inderberg EM; Wälchli S
BMC Biotechnol; 2020 Jun; 20(1):30. PubMed ID: 32487146
[TBL] [Abstract][Full Text] [Related]
10. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
11. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells.
Aparicio C; Belver M; Enríquez L; Espeso F; Núñez L; Sánchez A; de la Fuente MÁ; González-Vallinas M
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769211
[TBL] [Abstract][Full Text] [Related]
12. Cancer Immunology and CAR-T Cells: A Turning Point Therapeutic Approach in Colorectal Carcinoma with Clinical Insight.
Ray SK; Meshram Y; Mukherjee S
Curr Mol Med; 2021; 21(3):221-236. PubMed ID: 32838717
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
14. CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.
Hovhannisyan L; Riether C; Aebersold DM; Medová M; Zimmer Y
Mol Cancer; 2023 May; 22(1):82. PubMed ID: 37173782
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
16. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T; Yu SK; Xiang Y; Lu KH; Sun M
Front Immunol; 2022; 13():936496. PubMed ID: 35903099
[TBL] [Abstract][Full Text] [Related]
17. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
18. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
19. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
Alcantara M; Du Rusquec P; Romano E
Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880
[TBL] [Abstract][Full Text] [Related]
20. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
